Abstract: The priority review voucher scheme is a strong market-driven
incentive which complements existing incentives for pharmaceutical research on
neglected diseases. Contrary to other market based incentives, the PRV
reconciles the need for innovation with generic manufacturers' business
plans – since the PRV scheme does not delay generic competition while
extending effective patent life.